Deutsche Bank
VRNA

Deutsche Bank’s Verona Pharma VRNA Stock Holding History

Deutsche Bank’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-59
Closed – – 4423
2021
Q3 		$0 Buy
59
+1
+2% +$6 ﹤0.01% 4696
2021
Q2 		$0 Buy
+58
New +$402 ﹤0.01% 4813
2021
Q1 		– Sell
-117
Closed -$1K – 4675
2020
Q4 		$1K Buy
+117
New +$790 ﹤0.01% 4390
2020
Q1 		– Sell
-442
Closed -$2K – 4856
2019
Q4 		$2K Buy
442
+68
+18% +$297 ﹤0.01% 4857
2019
Q3 		$1K Sell
374
-9,900
-96% -$44.2K ﹤0.01% 4821
2019
Q2 		$52K Sell
10,274
-1,400
-12% -$8.54K ﹤0.01% 4497
2019
Q1 		$75K Buy
11,674
+5,500
+89% +$35.8K ﹤0.01% 4417
2018
Q4 		$55K Sell
6,174
-243
-4% -$2.76K ﹤0.01% 4448
2018
Q3 		$80K Sell
6,417
-50
-0.8% -$645 ﹤0.01% 4575
2018
Q2 		$88K Buy
6,467
+4,766
+280% +$80.1K ﹤0.01% 4593
2018
Q1 		$34K Buy
1,701
+1,101
+184% +$15.9K ﹤0.01% 4872
2017
Q4 		$7K Buy
+600
New +$7.79K ﹤0.01% 4821

Other funds holding VRNA

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Deutsche Bank's VRNA Position: Q4 2021 in Review

Deutsche Bank sold out of Verona Pharma (VRNA) in Q4 2021, closing a stake of 59 shares.

Deutsche Bank first reported a position in VRNA in Q4 2017 and held it in 12 quarters. The position peaked at $88K in Q2 2018. 42 funds tracked by Wall St. Rank hold VRNA as of Q4 2021.

  • Deutsche Bank reported no remaining Verona Pharma position as of Q4 2021 after selling out during the quarter.
  • Deutsche Bank sold 59 Verona Pharma shares in Q4 2021.
  • Deutsche Bank first reported a position in Verona Pharma in Q4 2017 and held it in 12 quarters.
  • Deutsche Bank's Verona Pharma position peaked at $88K in Q2 2018.
  • 42 funds tracked by Wall St. Rank held Verona Pharma as of Q4 2021.

Based on Deutsche Bank's 13F filing for Q4 2021, filed 11 Feb 2022.